Independent fund research. Built on SEC filings.

How we research funds

ETF · Health Care Sector · T. Rowe Price

T. Rowe Price Health Care ETF (TMED)

Ticker TMED · · Holdings as of Jun 30, 2026

Expense ratio
0.44%$44/yr per $10k
Net assets
$23.0Mall share classes
Holdings
102

Bottom line

Is TMED a good fund? The bottom line

TMED is an actively managed health care sector ETF from T. Rowe Price.

It charges 0.44% — about $44 a year on every $10,000 invested, cheaper than 85% of health care sector funds we track.

With $23.0 million in net assets and 102 holdings, its largest position is Eli Lilly & Co (16.7%) and the top 10 make up 47.5% of the portfolio.

What stands out

  • Low cost: cheaper than 85% of health care sector peers

What to watch

  • Small fund ($23.0 million) — small funds are likelier to close

Updated Nov 19, 2026

What TMED invests in

The fund seeks long-term capital appreciation.

The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in the securities of health care companies. The fund defines health care companies as companies engaged in health care innovations, such as developing new and effective therapies; pharmaceuticals; biotechnology; life sciences tools and services; managed health care; and/or health care equipment, supplies, providers, services, distributors, and facilities. The fund references the MSCI GICS (Global Industry Classification Standard) Health Care sector to identify such companies. Any derivatives that provide exposure to the investment focus suggested by the funds name, or to one or more market risk factors associated with the investment focus suggested by the funds name, are counted (as applicable) toward compliance with the funds 80% investment policy. As a fundamental policy, the fund…

From the fund's prospectus (filed Feb 25, 2026).

What TMED costs

On a $10,000 investment, TMED's 0.44% expense ratio costs about $44 a year. The prospectus estimates $555 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full TMED fee table →

TMED top 10 holdings

#Holding% of fund
1Eli Lilly & Co16.71%
2Unitedhealth Group Inc6.52%
3Gilead Sciences Inc4.44%
4Thermo Fisher Scientific Inc4.11%
5Danaher Corp2.96%
6Cencora Inc2.75%
7Agilent Technologies Inc2.61%
8Alnylam Pharmaceuticals Inc2.60%
9Intuitive Surgical Inc2.43%
10Insulet Corp2.38%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 47.5% of the fund. See all top 25 holdings and asset mix →

Alternatives to TMED

More funds like TMED →

TMED FAQ

What is the expense ratio of TMED?
TMED's expense ratio is 0.44%, which works out to about $44 a year for every $10,000 invested. The prospectus estimates total costs of $555 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is TMED a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 85% of health care sector peers; small fund ($23.0 million) — small funds are likelier to close. This is general information, not personalized advice.
What does TMED hold?
TMED's largest holdings are Eli Lilly & Co (16.7%), Unitedhealth Group Inc (6.5%), Gilead Sciences Inc (4.4%), Thermo Fisher Scientific Inc (4.1%), Danaher Corp (3.0%). It holds 102 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
Who manages TMED?
TMED is offered by T. Rowe Price through T. Rowe Price Exchange-Traded Funds, Inc..